GlassScriptPhysician profile
Jacob T Dean
NPI 1932172467
$7,660.45
in general payments reported to CMS, 2019-2025
47 companies · $969 in 2025
The $969 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,535 · 2020: $294 · 2021: $769 · 2022: $1,029 · 2023: $1,667 · 2024: $1,396 · 2025: $969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,032.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,263.80 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $913.08 | 2019-2024 | Xarelto, Spravato |
| Abbvie INC. | $731.68 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $581.95 | 2019-2025 | |
| Novo Nordisk INC | $574.85 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $482.39 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $388.68 | 2019-2025 | Repatha, Evenity, Otezla |
| Lilly USA, LLC | $275.43 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.46 | 2019-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Dexcom, INC. | $145.96 | 2022-2024 | Dexcom G6 Transmitter |
| Radius Health, INC. | $145.81 | 2019-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $128.24 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.56 | 2019-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $125.76 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $120.43 | 2019-2024 | Vaxneuvance, Gardasil, Gardasil 9 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $119.27 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $108.60 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.57 | 2019-2022 | |
| Amarin Pharma, INC. | $96.04 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $87.61 | 2022-2024 | Rexulti, Abilify Maintena |
| Abbott Laboratories | $82.40 | 2023-2024 | Freestyle Libre 3 |
| Corcept Therapeutics | $77.82 | 2022-2024 | Korlym |
| Allergan, INC. | $59.72 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $55.26 | 2024 | Voquezna |
| Astellas Pharma US INC | $54.38 | 2019-2024 | Myrbetriq, Veozah |
| Medtronic, INC. | $47.15 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $46.52 | 2021 | |
| Sanofi Pasteur INC. | $45.00 | 2019-2020 | |
| Axsome Therapeutics, INC. | $42.83 | 2025 | Symbravo, Auvelity |
| Xeris Pharmaceuticals, INC. | $36.26 | 2022-2023 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.87 | 2025 | Caplyta |
| Cequr Corporation | $29.90 | 2024-2025 | Cequr Simplicity |
| Regeneron Healthcare Solutions, INC. | $28.10 | 2019 | |
| Eisai INC. | $28.02 | 2019 | |
| Seqirus USA INC | $26.64 | 2022-2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Neurocrine Biosciences, INC. | $22.81 | 2025 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Bard Peripheral Vascular, INC. | $19.77 | 2024 | Venclose Maven Catheter |
| Esperion Therapeutics, INC. | $18.92 | 2024 | Nexletol |
| Tandem Diabetes Care, INC. | $18.91 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Vanda Pharmaceuticals INC. | $17.66 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.34 | 2019 | |
| Shield Therapeutics INC | $14.83 | 2025 | |
| Scilex Pharmaceuticals INC. | $14.24 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.36 | 2019 | |
| Averitas Pharma INC. | $13.13 | 2024 | Qutenza |
| Valeritas, INC. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.